Aisling Capital Management portfolio
Private equity or venture capitalPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 13, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Aisling Capital Management reported a $472M portfolio of 14 positions to the SEC as of the end of Q2 2026. Its largest positions are BBIO, GLUE, SNDX.
Sections with a free account
What changed this quarter
2 positions with a change (1 new, 1 trimmed). 1 is listed here: those of 0.5 points of the portfolio or more (up to 12).
- BridgeBio Pharma−9.8%fewer sharesReduced79.4% → 72.5%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- BridgeBio PharmaBBIO72.5%
- Monte Rosa TherapeuticsGLUE8.0%
- Syndax PharmaceuticalsSNDX6.1%
- COMPASS PathwaysCMPS4.3%
- Bicara TherapeuticsBCAX3.6%
- BridgeBio Oncology TherapeuticsBBOT1.6%
- Scholar Rock HoldingSRRK0.9%
- UroGen PharmaURGN0.8%
- Biomea FusionBMEA0.6%
- Aclaris TherapeuticsACRS0.5%
- Eupraxia PharmaceuticalsEPRX0.5%
- vTv TherapeuticsVTVT0.4%
- Marker TherapeuticsMRKR0.1%
- Onkure TherapeuticsOKUR0.1%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 14
Q2 2026: 99%
Q2 2026: 4.1%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Private equity or venture capital, per its Form ADV of Mar 27, 2026 (high confidence).
The data, as reported: AISLING CAPITAL MANAGEMENT LP (CRD 269994): 7.B private funds: 2 pe (gross assets $716M); 5.D assets by client type: pooled vehicles 100% (of $716M) · 13F: 86% of the portfolio was already held when the stock started trading
The type comes from a rule applied to that data. If it looks wrong, tell us.
Not counted as a concentrated manager: a single position is more than 70% of the portfolio; it is a private equity or venture firm; its stocks are usually holdings that went public. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Kadensa CapitalInvestment firm · $469M
- Magnolia GroupInvestment firm · $476M
- ValueworksInvestment firm · $479M
- United American Securities Inc. (d/b/a UAS Asset Management)Investment firm · $464M
- Mudita Advisors LLPInvestment firm · $481M
- Gamma As Sector$461M